Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dementia01:30

Dementia

632
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
632
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

4.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.7K
Neural Regulation01:37

Neural Regulation

43.8K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.8K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Blunted response of caudal locus coeruleus to arousing stimuli in Parkinson's disease.

Brain : a journal of neurology·2026
Same author

The COMPEX-trial: computer-based cognitive rehabilitation to improve executive function versus unspecific training in patients after stroke, cardiac arrest or in Parkinson's disease: study protocol for a randomized controlled trial.

Trials·2026
Same author

Diagnostic Value of Glycocalyx Shedding in Blood for Differentiating between Parkinson's Disease and Multiple System Atrophy.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Antipsychotics for Parkinson's disease: a protocol for a systematic review with network meta-analysis and trial sequential analysis.

BMJ open·2025
Same author

Deep brain stimulation for Parkinson's disease: systematic review with meta-analysis and trial sequential analysis.

BMJ medicine·2025
Same author

Mild cognitive impairment is not predictive of dementia up to 15 years after subthalamic deep brain stimulation in Parkinson's disease.

Journal of Parkinson's disease·2025

Related Experiment Video

Updated: Mar 5, 2026

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

11.4K

[Lewy body dementias].

Annemette Løkkegaard1, Lise Korbo

  • 1annemette.loekkegaard@regionh.dk.

Ugeskrift for Laeger
|March 24, 2017
PubMed
Summary
This summary is machine-generated.

Lewy body dementias, including dementia with Lewy bodies and Parkinson disease dementia, are common but underdiagnosed. Improved diagnosis and understanding of pathogenesis are crucial for developing effective treatments.

More Related Videos

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.4K
Technique for Intranasal Administration of α-Synuclein Aggregates
04:49

Technique for Intranasal Administration of α-Synuclein Aggregates

Published on: November 8, 2024

1.2K

Related Experiment Videos

Last Updated: Mar 5, 2026

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

11.4K
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.4K
Technique for Intranasal Administration of α-Synuclein Aggregates
04:49

Technique for Intranasal Administration of α-Synuclein Aggregates

Published on: November 8, 2024

1.2K

Area of Science:

  • Neuroscience
  • Neurology
  • Geriatrics

Background:

  • Dementia with Lewy bodies (DLB) and Parkinson disease dementia (PDD) share underlying pathophysiology, collectively termed Lewy body dementias (LBDs).
  • LBDs represent the second most frequent cause of dementia, yet often receive insufficient clinical attention and are frequently misdiagnosed.
  • This diagnostic uncertainty complicates patient management and hinders therapeutic advancements.

Purpose of the Study:

  • To summarize current diagnostic criteria for LBDs.
  • To review the role of imaging and biomarkers in LBD diagnosis.
  • To outline current treatment recommendations and future challenges in LBD management.

Main Methods:

  • Literature review and synthesis of existing diagnostic criteria for DLB and PDD.
  • Examination of current evidence for neuroimaging and fluid biomarkers in LBD diagnosis.
  • Compilation of established treatment guidelines and identification of research gaps.

Main Results:

  • Diagnostic criteria for LBDs are presented, emphasizing the overlap in pathophysiology.
  • The utility of various imaging modalities and biomarkers in differentiating LBDs is discussed.
  • Current therapeutic strategies and their limitations are summarized.

Conclusions:

  • Accurate diagnosis of LBDs is critical for optimal patient care.
  • Further research into the pathogenesis of LBDs is needed to develop disease-modifying treatments.
  • Refined diagnostic approaches and biomarker development are essential for future therapeutic breakthroughs.